6 news items
KAZIA REPORTS SUCCESSFUL STAGE 1 COMPLETION OF THE EVT801 PHASE 1 CLINICAL TRIAL IN ADVANCED CANCER PATIENTS
KZIA
1 May 24
investigators
Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseases
KZIA
21 Mar 24
in Sydney, Australia.
Our lead program is paxalisib, an investigational brain-penetrant inhibitor
Kazia announces presentation of new data at AACR Annual Meeting
KZIA
13 Mar 24
.
Our lead program is paxalisib, an investigational brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed
Stocks Making Waves: Insights into Key Developments and Potential VTAK, TBIO, OCEA, ONMD, KZIA
KZIA
OCEA
ONMD
26 Feb 24
revealed the early completion of a two-part clinical trial after successfully reaching its primary endpoint. Initiated by the investigator, the trial
What's Going With Australia-Based Cancer Firm Kazia Therapeutics On Wednesday?
KZIA
21 Feb 24
as per data from Benzinga Pro.
The investigator-initiated trial evaluated the use of paxalisib (an oral PI3K/mTOR dual inhibitor) with radiation
oxuroaal5s6wwah1 we76i13l0zzysx47o113efl1
KZIA
21 Feb 24
to date of an important two-part Phase I trial. This investigator-initiated trial evaluated the use of paxalisib (an oral PI3K/mTOR dual inhibitor
- Prev
- 1
- Next